Influenza 2026_Trivalent and quadrivalent vaccine options
This factsheet provides information to support health professionals in explaining the differences between trivalent (TIV) and quadrivalent (QIV) influenza vaccines available in 2026.
Overview
References
1. Mokalla VR, Gundarapu S, Kaushik RS, Rajput M, Tummala H. Influenza Vaccines: Current Status, Adjuvant Strategies, and Efficacy. Vaccines. 2025;13(9):962.
2. WHO National Influenza Centre HIT. Recommendation for seasonal influenza vaccine composition for New Zealand for 2026. Wellington: PHF Science/New Zealand Institute for Public Health and Forensic Science; 2025.
3. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet Infectious diseases. 2012;12(1):36-44.
4. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC infectious diseases. 2013;13:343.
5. Caini S, Meijer A, Nunes MC, Henaff L, Zounon M, Boudewijns B, et al. Is influenza B/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases. medRxiv. 2023:2023.09.25.23296068.
6. Vesikari T, Nauta J, Lapini G, Montomoli E, van de Witte S. Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study. International Journal of Infectious Diseases. 2020;92:29-37.
